NxStage Medical (NSDQ:NXTM) was founded in 1999 on the premise that patients with chronic kidney disease would benefit from bringing hemodialysis out of the clinic and into their homes. Seventeen years later, NxStage founder & CEO Jeff Burbank’s hypothesis has proven out. His Lawrence, Mass.-based company is topping more than $300 million in annual sales and, more […]
NxStage Medical Inc.
NxStage inks home hemodialysis deal with Satellite Health
NxStage Medical (NSDQ:NXTM) said today it inked a 3-year home hemodialysis supply agreement with Satellite Healthcare. Satellite, a non-profit group, is the 6th-largest dialysis and kidney disease treatment provider in the U.S. The deal will put NxStage’s Nx2me connected health platform in the hands of Satellite’s home hemodialysis patients. “We’re delighted that our depth of experience and […]
NxStage Medical jumps on Baxter’s exit from the home hemodialysis market
Share prices for NxStage Medical (NSDQ:NXTM) jumped this week after Baxter (NYSE:BAX) CEO Joe Almeida said the company is pulling the plug on its Vivia home hemodialysis device. Almeida, speaking at the Goldman Sachs investor conference June 7, said he evaluated the home dialysis market after he took over the corner office in October 2015. “That […]
NxStage touts home hemodialysis studies
NxStage Medical (NSDQ:NXTM) today touted data from studies of its Nx2me connected health technology and home hemodialysis systems, which the company plans to present at the 2016 Annual Dialysis Conference in Seattle later this month. In a study of 328 patients treated with the company’s HHD using its Nx2me platform, NxStage reported a 44% reduction […]
NxStage slumps despite Q1, FY2015 beats
NxStage saw shares plummet after releasing earnings that barely squeaked by Street expectations for their 4th quarter and full fiscal year 2015. The Lawrence, Mass.-based company reported losses of $2.8 million, or 4¢ per share, on sales of $89.8 million for the 3 months ended December 31. That amounts to a 43.7% reduction in losses […]
NxStage Medical jumps on Q3 beat-and-raise, reveals pipeline
NxStage Medical (NSDQ:NXTM) shares started up today as investors reacted to beat-and-raise results for the home hemodialysis company’s 3rd-quarter and details about its development pipeline. Lawrence, Mass.-based NxStage said it narrowed its losses by -47.8% to -$1.7 million, or -3¢ per share, on sales growth of 14.9% to $86.5 million compared with Q3 2014. The […]
NxStage reveals next-gen hemo, peritoneal dialysis systems
NxStage Medical (NSDQ:NXTM) announced 3 new products in the pipeline for the dialysis-focused device company during a conference call discussing their quarterly earnings last week. Included in the announcements was a next-generation portable hemodialysis system usable at home or in care centers, a new, simplified peritoneal dialysis machine and a critical care system. “In short, […]
NxStage teases at new pipeline products, announces Q2 earnings
NxStage Medical (NSDQ:NXTM) yesterday celebrated the 10 year anniversary mark for FDA approval of its System One home hemodialysis, announced new pipeline developments and Q2 earnings that beat expectations. The pipeline announcements from Lawrence, Mass.-based were said to include a next generation hemodialysis system, peritoneal dialysis system and a new critical care system, the company said. “Over […]
UPDATE: Outset Medical raises $91m for all-in-one dialysis system
Outset Medical, previously Home Dialysis Plus, said it raised $91 million in a new funding round, with $51 million in equity and $40 million in debt funding. Funds are slated to continue development and promotion of its Tablo all-in-one dialysis system. The $51 million round of equity funding was led by new investor Fidelity Research […]